Tufts-NEMC researchers identify enzyme that activates cancer cell growth and invasion

February 10, 2005

Boston, Mass. - Researchers from Tufts-New England Medical Center have identified a long-sought-after enzyme that interacts with a specific protease-activated receptor, PAR1, on breast cancer cells. The study authors identified metalloprotease-1 as the molecular scissors that activates PAR1 resulting in cancer cell invasion and tumor growth. They were able to block the spread of the breast cancer in animals using novel compounds called pepducins that act on the inside surface of the cell downstream of the enzyme and receptor. Their study appears in the February 11 edition of the journal Cell.

PARs are a unique class of receptors that have long been known to play critical roles in blood clotting, inflammation and growth of blood vessels. More recently, PAR1 has been linked with the invasive and metastatic properties of many different kinds of cancers, however, it was not known how the receptor was being activated in tumors.

"We were surprised to find that the cancer cell itself did not provide the missing protease. We found that the protease was being secreted by the surrounding host cells. This is an example of a cancer cell manipulating the host to provide the key missing ingredient, namely the protease," said Athan Kuliopulos, MD, PhD, of Tufts-NEMC's Molecular Oncology Research Institute and Hematology-Oncology Division, and the study's lead author. "The MMP-1 protease was thought to be mainly involved in cleavage of collagen. This means that MMP-1 is not only cutting up the tough collagen matrix that surrounds cancer cells, it is also activating PAR1 to enable the cancer to invade into other tissues."

The researchers identified several cell-penetrating compounds called pepducins that block activated PAR1 from triggering cancer invasion and angiogenesis. Tufts-NEMC has filed patent applications for these pepducins and will be exploring further research in this area.

"We believe that blocking the MMP-1/PAR1 pathway with the pepducins described in our study could provide a novel therapeutic approach for treating invasive cancers and possibly other tissue remodeling processes such as inflammation and atherosclerosis," said Kuliopulos.
-end-
The other scientist-researchers on the study were Adrienne Boire, PhD, of Tufts-NEMC's MORI and Tufts University School of Medicine's Department of Biochemistry, Lidija Covic, PhD, of MORI and the Medical Center's Division of Hematology-Oncology, Anika Agarwal, MD, and Susanne Jacques, PhD, of MORI, and Sheida Sherifi, MD, formerly at NEMC, now in the Department of Pathology at Mt. Auburn Hospital.

Published in Cell, Volume 120, Number 3, February 11, 2005, pages 303-313.
http://www.cell.com/content/article/abstract?uid=PIIS0092867404012103

Cell Press

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.